Mangaluru: Drunk man misbehaves with woman; gets thrashed by her son

Mangaluru, May 19: With lockdown 4.0 coming into force, the Karnataka State Road Transport Corporation (KSRTC) started bus services from Mangaluru to various destinations today.

According to officials, buses started plying from Mangaluru to Bengaluru, Mysuru, Shivamogga, Hubballi and other areas with limited passengers. A bus, which left for Bengaluru from Mangaluru had less than 30 passengers on board.

“Depending on the demand, the buses will be operated with 50% of the capacity. Measures have been taken to ensure that social distancing norms are adhered to while purchasing tickets from the counter,” said S N Arun, KSRTC Divisional Controller.

However, the KSRTC is yet to take a decision on operating Nagarasarige buses in the city. 

“Only those destinations, which can be reached by 7 pm has been considered by the KSRTC while operating the buses. As a result, after 11 am, no buses will travel to Bengaluru from Mangaluru. Further, permission will not be accorded for the travelling of pregnant women, children below 10 years old and senior citizens above 60 years old. Thermal scanning is used for checking the temperature of the passengers before boarding the buses. All the buses are sanitised after each trip,” he said.

Further, he said the contact number, name and address of the passengers are collected by the officials during the travel.

Mangaluru, Jan 24: The Srushti Kala Vidyalaya will be conferring it's 'Srushti Kalabhushan Award' to ace Yakshagana Bhagvatha Patla Sathish Shetty.

The award ceremony will be held at RV Dental College and Hospital in JP Nagar, Bengaluru on February 2, as part of the decennial celebrations of the Vidyalaya.

Chayapathi Kanchibail, founder of the Vidyalaya, said, "The award is being given to Shetty for his services to promote the art of Yakshagana and for his welfare work through the Yakshadhruva Patla Foundation."

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.